Siqing Li, MD, is Enterostomal Therapist, Department of Gastrointestinal Surgery, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China. Lanpeng Chen, MD, is Lecturer, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, China. Also at Fifth Affiliated Hospital of Sun Yat-sen University, Zhaoxia Yang, MS, is Enterostomal Therapist; Wenxin Luo, MS, is Gastrointestinal Surgery Head Nurse, Department of Gastrointestinal Surgery; Liping Zhong, MS, is Enterostomal Therapist, Radiological Department; Yuxia Liu, MS, is Gastrointestinal Surgery Nurse, Department of Gastrointestinal Surgery; Jianmin Chen, MS, is Gastrointestinal Surgery Nurse, Department of Gastrointestinal Surgery; Lihong Xu, MS, is Gastrointestinal Surgery Nurse, Department of Gastrointestinal Surgery; Minyi Xie, MD, is Enterostomal Therapist and Head Nurse, Surgical Department; and Xiaoyue Yang, MS, is Director, Nursing Department.
Adv Skin Wound Care. 2022 Nov 1;35(11):1-8. doi: 10.1097/01.ASW.0000889852.91765.ad.
To assess the efficacy of Sanyrene liquid dressing (Urgo Medical) in preventing radiation dermatitis (RD) among patients with cancer after radiotherapy.
The authors searched the China National Knowledge Infrastructure, SinoMed, WanFang Data, PubMed, Web of Science, EMBASE, and the Cochrane Library databases for articles published from inception to January 2021.
The preliminary search identified 146 studies. After removing duplicates, applying exclusion criteria, and screening titles and abstracts, 19 studies met the inclusion criteria.
A standardized form was constructed to extract data from eligible studies. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies.
The authors identified a total of 19 studies involving 1,508 patients that assessed the effectiveness of Sanyrene liquid dressing in preventing RD in patients with cancer after radiotherapy. The findings suggested that Sanyrene decreases the total incidence of RD (odds ratio [OR], 5.00; 95% CI, 2.77-9.03; P < .00001), as well as the incidence of RD grade 2 (OR, 0.55; 95% CI, 0.36-0.85; P = .007), grade 3 (OR, 0.22; 95% CI, 0.09-0.57; P = .002), and grade 4 (OR, 0.32; 95% CI, 0.13-0.78; P = .01). In addition, in comparison with controls, Sanyrene liquid dressing improves the cure rate (OR, 8.18; 95% CI, 4.03-16.60; P < .00001) and delays the occurrence of RD (mean difference, 3.69; 95% CI, 3.03-4.36; P < .00001).
Sanyrene liquid dressing can decrease both the total incidence of RD and the incidence of RD above grade 2. It also improves the cure rate and delays the occurrence of RD. Thus, Sanyrene may be a superior option for preventing RD after radiotherapy. However, the findings were assessed as moderate- to low-quality evidence and more high-quality trials are needed to support this result.
评估 Sanyrene 液体敷料（Urgo Medical）预防癌症患者放疗后放射性皮炎（RD）的疗效。
作者检索了中国知网、中国生物医学文献数据库、万方数据、PubMed、Web of Science、EMBASE 和 Cochrane 图书馆数据库，检索时间截至 2021 年 1 月。
初步搜索确定了 146 项研究。剔除重复文献后，根据排除标准筛选标题和摘要，最终有 19 项研究符合纳入标准。
使用标准化表格从纳入研究中提取数据。两位审查员独立筛选文献、提取数据并评估纳入研究的偏倚风险。
作者共纳入 19 项研究，共 1508 例患者，评估了 Sanyrene 液体敷料预防癌症患者放疗后 RD 的疗效。结果表明，Sanyrene 可降低 RD 总发生率（比值比[OR]，5.00；95%置信区间[CI]，2.77-9.03；P<0.00001）、RD 2 级发生率（OR，0.55；95%CI，0.36-0.85；P=0.007）、RD 3 级发生率（OR，0.22；95%CI，0.09-0.57；P=0.002）和 RD 4 级发生率（OR，0.32；95%CI，0.13-0.78；P=0.01）。此外，与对照组相比，Sanyrene 液体敷料可提高治愈率（OR，8.18；95%CI，4.03-16.60；P<0.00001）和延迟 RD 发生（均数差，3.69；95%CI，3.03-4.36；P<0.00001）。
Sanyrene 液体敷料可降低 RD 总发生率和 2 级以上 RD 发生率，提高治愈率并延迟 RD 发生。因此，Sanyrene 可能是预防放疗后 RD 的一种较好选择。但是，这些发现被评估为中低质量证据，需要更多高质量的试验来支持这一结果。
